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ORIGINAL RESEARCH
Background. Acute mountain sickness (AMS) is an ever-increasing burden on the health sector. With reported incidences of greater than 
50%, coupled with the fact that recreational activities at high altitude are gaining increasing popularity, more persons are developing AMS. 
Physicians are therefore increasingly faced with the task of managing and preventing AMS. 
Objectives. The pathophysiology of AMS is poorly understood, with little understanding of risk factors for the development of AMS. This 
research aimed to identify epidemiological and physiological risk factors for development of AMS. 
Methods. This study is a questionnaire-based study conducted in London and at Everest Base Camp, in which 116 lowlanders were invited 
to participate and fill in a questionnaire to identify potential risk factors in their history that may have contributed to development of or 
protection against AMS.
Results. A total of 89 lowlanders enrolled in the study. Thirty-seven of the participants had AMS at Everest Base Camp, giving a 
prevalence of 42%. Of the demographic variables, only weight and body mass index (BMI) were statistically significantly associated with 
AMS, with those who weighed less or had a lower BMI more likely to get AMS. Previous high-altitude experience was also associated 
with AMS, with those who had such experience less likely to get AMS. 
Conclusion. Predicting AMS and furthering our understanding of the pathophysiology of AMS will be of tremendous benefit. Further 
research is needed in this regard.
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Acute mountain sickness (AMS) is defined as the 
presence of a headache in an unacclimatised individual 
who has recently arrived at high altitude, along with 
gastrointestinal symptoms, insomnia, dizziness and 
lassitude or fatigue. [1] At the Seventh International 
Hypoxia Symposium held at Lake Louise, Canada,[2] AMS was further 
subdivided into mild, moderate and severe, based on the clinical 
presentation. This formed the basis for the Lake Louise Score, according 
to which mild AMS is defined as headache, nausea, dizziness and 
fatigue during the first 12 hours after ascent to altitude. Moderate AMS 
occurs when there is moderate to severe headache with marked nausea, 
dizziness, lassitude, insomnia and fluid retention at high altitude for 
12 hours or more. Visitors to high altitude may also suffer from high-
altitude cerebral oedema (HACE) and high-altitude pulmonary oedema 
(HAPE). HAPE and HACE are not severe forms of AMS; they can exist 
in their own right without preceding AMS and may have an entirely 
different pathophysiology.
The pathophysiology of AMS is not clearly understood. Signals 
generated at high altitude may activate the trigeminovascular system 
(i.e. neurons in the trigeminal nerve that innervate cerebral blood 
vessels) by both chemical and mechanical stimulation, causing a 
headache.[3] Many investigators believe that AMS is due to mild 
cerebral oedema and that all new climbers to high altitude may 
have mild cerebral oedema. In those with moderate to severe AMS, 
neuro-imaging demonstrated vasogenic oedema.[4] Capillary leakage 
following hypoxia-induced damage to the blood-brain barrier also 
plays a role. Mediators such as vascular endothelial growth factor, 
inducible nitric oxide synthase and bradykinin are also being studied.
Several risk factors for the development of AMS have been 
identified; for example, speed of ascent greater than 300 - 500 m 
a day in the acclimatisation period, previous history of AMS or 
HAPE, obesity, migraine, persistence of a patent foramen ovale, 
Down syndrome, congenital pulmonary abnormalities, perinatal 
pulmonary vascular insult, and Holmes-Adie syndrome, are 
clinical conditions associated with susceptibility to AMS or 
HAPE. [5] This study was conducted at Everest Base Camp, with an 
altitude of 5 364 m. The incidence of AMS at Everest Base Camp 
has been reported to be as high as 57%.[6]
Approximately ten people a year die on Mount Kilimanjaro 
alone. [7] Millions of visitors travel each year to regions of high 
altitude, and the numbers are increasing as high altitude and 
extreme mountaineering become more accessible and ever more 
popular. It is evident that AMS will prove to be an ever-increasing 
burden on the healthcare industry. Identifying persons at increased 
risk of developing AMS and at an increased risk of progressing to 
HACE or HAPE will be invaluable to the high-altitude visitor as well 
as the healthcare professional.
Methods
Extreme Everest 2013 was an observational cohort study of human 
responses to progressive hypobaric hypoxia (during ascent) and 
subsequent normoxia (following descent), comparing sherpas (high-
altitude ancestry) with lowlanders (lowland ancestry). Studies were 
conducted in London (35 m) in the UK and Kathmandu (1 300 m), 
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Namche Bazaar (3 500 m) and Everest Base Camp (5 300 m) in Nepal. 
Of the 180 healthy volunteers departing from Kathmandu, 64 were 
sherpas and 116 were lowlanders. This research is a questionnaire-
based study conducted in London and at Everest Base Camp. All 
116 lowlanders participating in the Extreme Everest 2013 study were 
invited to take part in this study and to complete a questionnaire 
to identify potential risk factors in their history that may have 
contributed to development of AMS or protect against development 
of AMS. This cross-sectional, single-site study was limited to adults 
who are literate in English.
Procedure and design
At the testing sessions held at sea level in London volunteers 
were invited to participate in this study and to complete the study 
questionnaire. Thus the initial part of the questionnaire was completed 
at sea level in London, with the Lake Louise Score completed upon 
arrival at Everest Base Camp. Participants trekked in groups of up to 
14. All lowlanders flew to Kathmandu and spent one night there prior 
to flying to Lukla (2 800 m). All participants followed an identical 
ascent and descent profile. The ascent to Everest Base Camp from 
Kathmandu was completed over 11 days, with rest days built into the 
schedule to reduce the likelihood of AMS.
The data collected in the questionnaire included the following:
• Biographical information: Participant’s age, weight, height, 
gender, city of residence, previous high-altitude experience and 
previous episodes of AMS.
• Family history: Family history of heart attacks, cancer, high 
cholesterol, asthma, obesity, substance dependence, lung disease 
or high blood pressure.
• Personal medical conditions and medication use.
• A lifestyle evaluation questionnaire including exercise and 
fitness, nutrition, tobacco use, alcohol and drug use, emotional 
health, safety and disease prevention. (This questionnaire was 
developed by the United States Health and Human Services in 
2006 so that the public perform self-evaluations on themselves.)
• A nutritional assessment questionnaire, adapted to assess food-
related behaviour in the athlete. The higher the score, the poorer 
the participant’s dietary habits.
• The frequency, intensity, time (FIT) index of Kasari (unpublished 
master’s thesis, University of Montana, Missoula, 1976) which 
assesses frequency, intensity and time of exercise and sporting 
activity. This validated questionnaire was developed in the 1970s 
and shown to relate to aerobic fitness. It quantifies a respondent’s 
participation in any form of physical activity; with an increase 
in the frequency, intensity and time of exercise there is an 
accompanying increase in the index score and fitness.
• The Physical Activity Readiness Score (PAR-Q), a self-screening 
tool developed by the British Columbia Ministry of Health and 
Multidisciplinary Board on Exercise to identify individuals who 
may be not be suitable for commencing strenuous exercise.
• The Paffenbarger Physical Activity Score, a short, self-
administered questionnaire designed to measure participation in 
leisure-time physical activity. It consists of eight questions relating 
to daily activity; a physical activity index can be computed from 
the answers, providing an estimate of energy expenditure.
• The Lake Louise Score.[2]
Statistical analysis
Categorical data were described using frequency (percentage) and 
continuous data using median (interquartile range (IQR)). For 
comparisons between the two AMS groups (AMS, no AMS), the 
Mann-Whitney U-test was used for continuous variables and the 
χ2 test or Fisher’s exact test in the case of small expected counts for 
categorical variables. The non-parametric Mann-Whitney U-test was 
used as the sample size was small and the distributions of variables 
were non-normal. All statistical analyses were performed using SPSS 
version 21.0 (IBM, USA). All tests were two-sided and a p-value <0.05 
was considered to be statistically significant.
Ethical considerations
All participants were provided with patient information leaflets and 
all submitted written consent. The study design, risk management 
plan and protocols were approved (in accordance with the Declaration 
of Helsinki) both by the University College London Research Ethics 
Committee and the University College Committee on the Ethics of 
Non-National Health Service Human Research, and the Nepal Health 
Research Council.
Results
A total of 89 participants were enrolled into the study. The 
characteristics of the participants are presented in Table 1. Thirty-
seven of the participants had AMS at Everest Base Camp, giving a 
prevalence of 42% (95% confidence interval (CI) 31 - 53%). For the 
demographic variables only weight (p=0.033) and body mass index 
(BMI) (p=0.047) were statistically significantly associated with 
AMS. Those participants who weighed less or had a lower BMI were 
more likely to get AMS. Previous high-altitude experience was also 
associated with AMS (p=0.005), with those who had previous high-
altitude experience less likely to get AMS. 
None of the lifestyle evaluation subscale scores nor the overall 
lifestyle score was significantly associated with AMS (p>0.05 for all). 
Similarly, the nutritional assessment score and FIT score were not 
significantly associated with AMS (p=0.799 and p=0.817, respectively). 
Those participants whose permanent residence was above 900 m (n=7) 
were less likely to get AMS than those whose residence was at a lower 
altitude, but the difference was not statistically significant (p=0.233). 
Similarly, those with a moderate Paffenbarger Physical Activity Score 
and those who achieved a pass on the readiness scale were less likely 
to get AMS, but the results were not statistically significant (p=0.141 
and p=0.188, respectively). 
The family medical histories of participants are presented in Table 2. 
Only a family history of heart disease was statistically significantly 
associated with AMS (p=0.038), with those who had such a family 
history less likely to get AMS.
For the statistical analysis being overweight or obese were combined, 
and there was no statistically significant difference in BMI categories 
between the two AMS groups (p=0.171, χ2 test). BMI was left as a 
continuous variable for the results presented, and the difference between 
groups was statistically significant (as can be seen from Table 1).
Discussion
This cross-sectional study was conducted with the aim of identifying 
factors associated with a person’s risk of developing AMS. The 
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results largely conformed with those from existing research, with the 
exception of some interesting findings which will be discussed.
Does older age predispose one to developing AMS? This study 
showed no statistically significant protective benefit conferred by 
Table 1. Participant characteristics overall and by AMS group
Overall (N=89*) AMS (N=37) No AMS (N=52) p-value†
n (%)
Gender 0.32 
Male 44 (49) 16 (43) 28 (54)
Female 45 (51) 21 (57) 24 (46)
Smoker 0.63 
Yes 14 (16) 5 (14) 9 (17)
No 75 (84) 32 (86) 43 (83)
Height above sea level of permanent residence 0.23 
< 900 m 79 (92) 34 (97) 45 (88)
≥ 900 m 7 (8) 1 (3) 6 (12)
Previous high-altitude experience 0.01 
Yes 54 (61) 16 (43) 38 (73)
No 35 (39) 21 (57) 14(27)
Previous episode of AMS 0.46 
Yes 8 (9) 2 (5) 6 (12)
No 81 (91) 35 (95) 46 (88)
Paffenbarger Physical Activity Score 0.14 
Low 7 (8) 4 (11) 3 (6)
Moderate 63 (71) 22 (59) 41 (79) 
High 19 (21) 11 (30) 8 (15)
PAR-Q readiness 0.19 
Pass 73 (82) 28 (76) 45 (87)
Fail 16 (18) 9 (24) 7 (13)
Median (IQR)
Age (yr) (n=86) 35 (28 - 51.3) 37.5 (28.3 - 50.5) 33 (27.8 -52.3) 0.66
Weight (kg) (n=78) 73.5 (64 - 80.3) 68 (59 - 76) 75 (66 - 83.5) 0.03
Height (cm) (n=74) 174.5 (165.8 - 180.3) 173 (163.5 - 180) 176 (166.5 - 181) 0.31
BMI (n=71) 23.3 (22.1 - 25.7) 22.9 (20.9 - 24.7) 23.9 (22.4 -27.1) 0.05
Lifestyle evaluation (lower score is better)
Exercise/fitness score (possible range 4 - 12) 6 (4.5 - 8) 6 (4.5 - 8) 6 (4.3 - 8) 0.57
Nutrition score (possible range 4 - 12) 7 (6 - 8) 7 (5.5 - 7) 7 (6 - 8) 0.14
Tobacco use score (possible range 2 - 6) 2 (2 - 2) 2 (2 - 2) 2 (2 - 2) 0.74
Alcohol and drugs score (possible range 4 - 12) 6 (4 - 7) 6 (4 - 7) 6 (5 - 7.8) 0.33
Emotional health score (possible range 4 - 12) 5 (4 - 7) 5 (4 - 7) 5 (4 - 7) 0.73
Safety score  (possible range 5 - 15) 5 (5 - 6) 5 (5 - 6) 5 (5 - 6) 0.49
Disease prevention score (possible range 5 - 15) 8 (7 - 9) 8 (6 - 8.5) 7.5 (7 - 9) 0.36
Overall lifestyle score (possible range 28 - 84) 38 (36 - 43) 37 (34 - 43) 38.5 (36-43) 0.22
Nutritional assessment score (possible range 15 - 75) 35 (27.5 - 39) 34 (28 - 38.5) 35 (27 - 39) 0.8
FIT score (possible range 1 - 100) (n=77) 60 (48 - 80) 62 (48 - 80) 60 (48 - 80) 0.82
*Unless otherwise stated.
†All from Mann-Whitney U-test except for χ2 test and Fisher’s exact test.
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age, at least in the range of 19 - 74 years. 
However, other studies have showed that 
increased age conferred some benefit at high 
altitudes. For example, Roach et al.[8] studied 
the physiological and clinical response to 
moderate altitude (2 500 m) in 97 men and 
women aged 59 - 83 years, and found the 
incidence of AMS to be 16%, lower than that 
reported for younger persons. Even though 
20% of the participants had coronary artery 
disease, 34% had hypertension and 9% had 
lung disease, the incidence of AMS remained 
low. Gaillard et al.[9] reported that people over 
the age of 55 years were 2.6 times less likely 
to suffer from AMS than people younger than 
25 years, further suggesting that age might 
be a protective factor in developing AMS. A 
systematic review of the literature is required 
to answer this question definitively.
To date studies have shown that AMS is 
unrelated to gender. Hackett et al.[10] studied 
278 hikers at Pheriche in Nepal, and their 
results showed that gender did not predispose 
one to developing AMS. Honigman et al.[11] 
showed that women may be less susceptible 
to HAPE, but equally as prone to AMS as 
men. Wang et al.[12] also showed no difference 
in prevalence of AMS between genders. 
Similarly, there was no significant difference 
between genders in this study (p=0.324). 
Neither the lifestyle evaluation subscale 
scores nor the overall lifestyle score was 
significantly associated with AMS (p>0.05 
for all). Similarly, the nutritional assessment 
score and FIT score were not significantly 
associated with AMS (p=0.799 and p=0.817, 
respectively). Physical fitness was also not 
shown to be protective against AMS, which 
is in keeping with the literature. Milledge et 
al.[13] showed no correlation between AMS 
scores and hypoxic ventilatory response or 
VO2 max.
One of the risk factors proposed by Hackett 
et al.[4] is that of residing at an altitude below 
900 m: those participants whose permanent 
residence was above 900 m (n=7) were less 
likely to get AMS than those whose residence 
was at a lower altitude, but the difference was 
not statistically significant (p=0.233).
A prior history of AMS has been uniformly 
quoted as a risk factor by many authors. [1,8] 
This study showed that previous high-
altitude experience was also associated with 
AMS (p=0.005), with those who had previous 
high-altitude experience less likely to get 
AMS.
In this study participants who weighed 
less or had a lower BMI were more likely to 
get AMS, which is in keeping with recent 
findings. Richalet et al.[5] recently reported 
regular physical activity as a risk factor for 
development of AMS. It would make sense 
that a fitter person with a lower BMI would do 
better at high altitude – but both Richalet et 
al.[5] and this study have shown the opposite. 
This is an interesting subject to explore and 
investigate further.
Chronic medical conditions and a family 
history of conditions such as hypertension, 
coronary artery disease, mild chronic 
obstructive pulmonary disease and diabetes, 
as well as pregnancy, do not appear to affect 
susceptibility to high-altitude illness.[14] The 
family medical histories of the participants 
are presented in Table 2. Only a family 
history of heart disease was associated with 
AMS (p=0.038), with those who had a family 
history less likely to get AMS.
Smoking has not yet proven to be a risk 
factor for development of AMS. Gaillard et 
al.[9] studied two cohorts of 500 trekkers in 
the Annapurna region of central Nepal, and 
found no relationship between AMS and 
smoking habits. Similarly, no relationship 
between smoking and developing AMS was 
found in this study (Table 1).
Conclusion
This study showed that certain parameters, 
such an increased weight, an increased BMI 
and previous altitude experience, decrease 
the risk of developing AMS. Lifestyle-
scoring questionnaires did not predict 
those participants who might develop AMS. 
Furthermore, this study did not show a link 
between age, gender, fitness or smoking and 
the development of AMS. 
With ever-increasing number of people 
visiting areas of high altitude, further research 
in this regard is anticipated to further expand 
our knowledge and understanding of AMS.
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Table 2. Family history overall and by AMS group
Family history
Overall, n (%) 
(N=89)
AMS, n (%) 
(N=37)
No AMS, n (%) 
(N=52) p-value*
Any cancer 47 (53) 21 (57) 26 (50) 0.53
High blood pressure 27 (30) 9 (24) 18 (35) 0.30
High cholesterol levels 22 (25) 8 (22) 14 (27) 0.57
Asthma 21 (24) 8 (22) 13 (25) 0.71
Overweight 20 (23) 6 (16) 14 (27) 0.23
Myocardial infarction 15 (17) 8 (22) 7 (14) 0.31
Heart disease 13 (15) 2 (5) 11 (21) 0.04
Lung disease 8 (9) 1 (3) 7 (14) 0.13 
Substance dependencies 4 (5) 0 (0) 4 (8) 0.14 
*All from χ2 test except for Fisher’s exact test.
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